Cart
sales@molnova.com
Tralokinumab
CAS No. 1044515-88-9
Tralokinumab( —— )
Catalog No. M36676 CAS No. 1044515-88-9
Tralokinumab is a fully human IgG4 monoclonal antibody with a high affinity for IL-13 alone.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 439 | Get Quote |
|
| 5MG | 549 | Get Quote |
|
| 10MG | 867 | Get Quote |
|
| 25MG | 1242 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameTralokinumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionTralokinumab is a fully human IgG4 monoclonal antibody with a high affinity for IL-13 alone.
-
DescriptionTralokinumab, a fully human IgG4 monoclonal antibody, specifically binds with high affinity to IL-13 alone, preventing its interaction with the receptor and subsequent downstream signalling. Tralokinumab can be used for the research of the atopic dermatitis (AD).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetIL Receptor
-
RecptorIL Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1044515-88-9
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. A Wollenberg, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021 Mar;184(3):437-449.?
molnova catalog
related products
-
Apilimod
Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis.
-
Ustekinumab
Ustekinumab is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody.
-
Mogroside IIe
Mogroside IIe is a major bioactive component of unripe S. grosvenorii fruit that downregulates the IL-9/IL-9 receptor pathway.
